• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
AGRX

AGRX

Agile Therapeutics, Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD1.51

+0.05 (+3.42%)

Company Profile

CEO

Alfred F. Altomari

IPO Date

2014-05-23

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.48

Prev. Close

$1.46

Day Low

$1.44

Day High

$1.51

52W Low

$0.20

52W High

$2.63

Market Cap

$0.01B

Volume

0.12M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

21.1%

Avg Negative

13.2%

Avg Neutral

65.6%

News Feed

Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy

Seeking Alpha·7/30/2021·↑ positive

2 Penny Stocks Insiders Are Buying

Benzinga·7/30/2021·↑ positive

3 Penny Stocks Insiders Are Buying

Benzinga·7/29/2021·↑ positive

Agile Therapeutics, Inc.'s (AGRX) CEO Al Altomari on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·7/26/2021·↓ negative

Agile Therapeutics: Q2 Earnings Insights

Benzinga·7/26/2021·↓ negative

Agile Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on Monday, July 26, 2021

GlobeNewsWire·7/1/2021·↓ negative

Agile Therapeutics to Participate in the William Blair 41st Annual Growth Stock Conference

GlobeNewsWire·5/26/2021·↑ positive

Agile Therapeutics: Returning To Bullish Outlook After Encouraging Q1 Earnings

Seeking Alpha·5/8/2021·↑ positive

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/4/2021·↓ negative

Agile Therapeutics (AGRX) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/4/2021·↑ positive